A Study of UK-369,003 on the Safety and Efficacy in Patients With COPD

A Multi-Centre, Multinational, Randomized, Double-Blind, Placebo Controlled, Proof Of Concept Trial To Assess The Effects Of A Subject-Optimized Dose Of UK-369,003 On Exercise Capacity In Subjects With Chronic Obstructive Pulmonary Disease

Status

Completed

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00163098

Enrollment

136

Registered

2005-09-13

Start date

2004-12-31

Completion date

2005-12-31

Last updated

2006-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Disease, Chronic Obstructive

Brief summary

A randomised, controlled study investigating the effect of UK-369,003 on exercise tolerance in patients with COPD

Interventions

DRUGUK-369,003

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

35 Years to 75 Years

Healthy volunteers

Inclusion criteria

* GOLD criteria 2 to 4 * 10 pack year history of smoking

Exclusion criteria

* Women of child bearing potential

Design outcomes

Primary

Measure	Time frame
Effect on exercise tolerance	—

Secondary

Measure	Time frame
Effect on lung function and quality of life	—

Countries

Argentina, Australia, Germany, India, United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026